Emerging footprint in large molecules within biotechnology, cell and gene therapies

Global presence in
small-molecule
pharmaceutical ingredients
and finished dosages

Global presence in
small-molecule pharmaceutical
ingredients and finished dosages

Best-in-class, future-ready facilities staffed by meritorious personnel

Best-in-class, future-ready facilities staffed by meritorious personnel

Integrated processes for development, manufacturing, and supply-chain solutions

Committed to sustainable, efficient, and scalable operations

Committed to sustainable, efficient, and scalable operations

Impeccable regulatory
compliance track record
since the commencement
of operations.

Impeccable regulatory
compliance track record
since the commencement
of operations.

One quality standard for all markets.

Core emphasis on safety, environment, and society.

Core emphasis on safety, environment, and society.

Press releases and announcements

16 Sep 2024

Press Release - Laurus Labs Inaugurates New State of the Art R&D Facility at IKP Knowledge Park

13 Sep 2024

Press Release - Laurus Labs Concludes Successful US FDA Audit for API Manufacturing Facility at Hyderabad

25 Jul 2024

Press Release - Laurus Labs Announces Q1 FY 25 Results Revenues at ₹ 1,195 Cr; EBITDA at ₹ 171 Cr

25 Apr 2024

Press Release - Financial results for the quarter and year ended March 31, 2024

25 Jan 2024

Press Release - JV Agreement with KRKA

We value your privacy

We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic.By Clicking “Accept”, you consent to our use of cookies. Cookie Policy